Ocugen, Inc. 8-K

What Happened

• Ocugen, Inc. filed an 8-K reporting the results of its virtual 2026 Annual Meeting of Stockholders held June 11, 2026. A total of 139,628,075 shares were represented virtually or by proxy.
• Stockholders elected two Class III directors: Kirsten Castillo, MBA (56,242,944 For; 8,476,217 Withheld; 74,908,914 broker non-votes) and Satish Chandran, Ph.D. (62,604,983 For; 2,114,178 Withheld; 74,908,914 broker non-votes).
• PricewaterhouseCoopers LLP was ratified as the Company’s independent registered public accounting firm for fiscal 2026 (136,784,245 For; 1,002,550 Against; 1,841,280 Abstentions).
• Advisory vote on executive compensation (say-on-pay) passed (49,968,948 For; 13,245,090 Against; 1,505,123 Abstentions; 74,908,914 broker non-votes). Stockholders also chose a one-year frequency for future advisory votes on executive pay (57,545,540 For 1 Year).
• Separately, Ocugen appointed Mohamed Genead, M.D., M.Sc., as Chief Medical Officer effective June 11, 2026 (he had served as Acting/Interim CMO since May 8, 2026).

Key Details

• Total shares represented: 139,628,075.
• Director election tallies: Castillo — 56,242,944 For; Chandran — 62,604,983 For.
• Auditor ratification: PwC — 136,784,245 For.
• Say-on-pay and frequency: 49,968,948 For on pay; 57,545,540 voted for annual advisory votes.

Why It Matters

• Board composition and governance: Election of two directors and the ratification of PwC affect company oversight and audit continuity—important for investor confidence.
• Executive compensation oversight: Passing the say-on-pay and selecting annual advisory votes means shareholders want regular, yearly review of named executive officer pay.
• Management continuity: Appointment of Dr. Mohamed Genead as permanent Chief Medical Officer provides clarity on clinical leadership, which is material for a clinical-stage biotech where trial progress and regulatory interactions matter.